(no title)
Gatsky
|
2 years ago
Disagree. I change practice on Monday after a single quality trial. Pick up any society guideline, only a small amount of the recommendations rely on meta-analyses. Look at immunotherapy or antibody drug conjugates, revolutionary therapies that arrived one trial at a time.
haldujai|2 years ago
But oncology is a very big field…
For example, the majority diagnostic testing guidelines are based on meta-analyses.
FYI since you asked to pick one, let's take a look at NCCN. Not sure where you're drawing your conclusion that most evidence is from phase III RCTs:
"[Q] Quality and quantity of evidence refers to the number and types of clinical trials relevant to a particular intervention. To determine a score, panel members may weigh the depth of the evidence, i.e., the numbers of trials that address this issue and their design. The scale used to measure quality of evidence is:
5 (High quality): Multiple well-designed randomized trials and/or meta-analyses
4 (Good quality): One or more well-designed randomized trials
3 (Average quality): Low quality randomized trial(s) or well-designed non-randomized trial(s)
2 (Low quality): Case reports or extensive clinical experience
1 (Poor quality): Little or no evidence"
"The overall quality of the clinical data and evidence that exist within the field of cancer research is highly variable, both within and across cancer types. Large, well designed, randomized controlled trials (RCTs) may provide high-quality clinical evidence in some tumor types and clinical situations. However, much of the clinical evidence available to clinicians is primarily based on data from indirect comparisons among randomized trials, phase II or non-randomized trials, or in many cases, on limited data from multiple smaller trials, retrospective studies, or clinical observations. In some clinical situations, no meaningful clinical data exist and patient care must be based upon clinical experience alone. Thus, in the field of oncology, it becomes critical and necessary (where the evidence landscape remains sparse or suboptimal) to include input from the experience and expertise of cancer specialists and other clinical experts."
From an article:
"We identified 1124 potential systematic reviews from our survey of the 49 NCCN guidelines for the treatment of cancer by site. Five NCCN guidelines did not cite any systematic reviews."
https://www.nccn.org/guidelines/guidelines-process/developme...
https://jamanetwork.com/journals/jamaoncology/fullarticle/27...
https://www.nccn.org/guidelines/guidelines-with-evidence-blo...
Gatsky|2 years ago
I didn't say most evidence is from phase III RCTs, particularly if you include everything that happens in oncology as the denominator, only that meta-analyses were not that relevant. Most of the critical patient facing interventions have the backing of good quality trials, at least where it is reasonable and possible to do a trial. Also one of your citations is seemingly casting doubt on the value of meta-analyses in oncology, so somewhat confused about your point.
That paragraph from NCCN is quite interesting. It is describing medicine in general really, and belies the fact that oncology has probably one of the strongest evidence base across all medical fields. Take for example how many stents cardiologists have inserted long after contradictory evidence was available, or how many pointless back operations have been done, or how many people have sat through fruitless psychoanalysis.
prashp|2 years ago
Gatsky|2 years ago
haldujai|2 years ago
Although guidelines are just that (i.e. not mandatory to adhere to) I really doubt an oncologist in US/Canada "practices as they please".